tiprankstipranks
Trending News
More News >
Advertisement

PTH - ETF AI Analysis

Compare

Top Page

PTH

Invesco DWA Healthcare Momentum ETF (PTH)

Rating:60Neutral
Price Target:
$53.00
The overall rating of the Invesco DWA Healthcare Momentum ETF (PTH) reflects a mix of strengths and challenges across its holdings. Strong contributors like Medpace Holdings and Boston Scientific drive the fund’s rating with their robust financial performance and positive growth outlooks. However, weaker holdings such as Celcuity and Nektar Therapeutics, which face significant financial and valuation challenges, weigh on the overall score. A key risk factor for this ETF is its concentration in the healthcare sector, which can expose investors to industry-specific volatility and regulatory risks.
Positive Factors
Strong Top Holdings
Several of the largest positions, such as Nektar Therapeutics and Insmed, have delivered strong year-to-date gains, boosting the ETF’s overall performance.
Momentum in Health Care Sector
The ETF focuses on the health care sector, which has shown strong recent performance, aligning with its momentum-driven strategy.
Solid Short-Term Performance
The ETF has delivered strong returns over the past month and three months, indicating positive recent momentum.
Negative Factors
Sector Concentration Risk
Nearly all of the ETF’s exposure is in the health care sector, making it vulnerable to sector-specific downturns.
High Geographic Concentration
The ETF is heavily focused on U.S. companies, limiting diversification and exposure to international markets.
Above-Average Expense Ratio
The ETF charges a relatively high expense ratio compared to many other funds, which could eat into investor returns over time.

PTH vs. SPDR S&P 500 ETF (SPY)

PTH Summary

The Invesco DWA Healthcare Momentum ETF (PTH) is an investment fund that focuses on companies in the healthcare sector, such as Medpace Holdings and Boston Scientific. It uses a strategy to invest in healthcare businesses showing strong growth trends, including biotechnology, medical devices, and pharmaceuticals. This ETF is a good option for investors who want to benefit from the innovation and growth in healthcare, driven by factors like aging populations and new technologies. However, since it focuses heavily on healthcare, its performance can be affected by changes in that sector, making it less diversified than broader market ETFs.
How much will it cost me?The Invesco DWA Healthcare Momentum ETF (Ticker: PTH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on momentum-driven strategies within the healthcare sector.
What would affect this ETF?The Invesco DWA Healthcare Momentum ETF (PTH) could benefit from ongoing advancements in healthcare technology, an aging population driving demand for medical services, and increased investment in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, pricing pressures in the healthcare industry, and potential economic downturns that could reduce consumer spending on healthcare. Its focus on U.S.-based healthcare companies and momentum-driven strategy makes it sensitive to market volatility and sector-specific trends.

PTH Top 10 Holdings

The Invesco DWA Healthcare Momentum ETF is riding the wave of innovation in the healthcare sector, with biotech names like Cidara Therapeutics and Celcuity leading the charge thanks to strong momentum and positive outlooks from recent earnings calls. However, the fund faces headwinds from lagging names like Boston Scientific, which has struggled with bearish technical signals despite solid financial performance. With nearly all holdings rooted in U.S.-based healthcare companies, the ETF is heavily concentrated in biotech and medical devices, making it a high-risk, high-reward play for investors seeking exposure to cutting-edge healthcare advancements.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Cidara Therapeutics6.42%$8.01M$6.92B1078.44%
57
Neutral
Insmed5.09%$6.35M$44.13B179.30%
53
Neutral
Medpace Holdings4.86%$6.06M$17.42B83.08%
79
Outperform
Guardant Health4.70%$5.86M$14.39B214.26%
58
Neutral
Natera3.84%$4.80M$32.93B45.13%
68
Neutral
Celcuity3.65%$4.56M$4.68B627.70%
44
Neutral
Tenet Healthcare3.44%$4.29M$18.86B49.75%
72
Outperform
Nektar Therapeutics3.41%$4.26M$1.19B258.65%
49
Neutral
Boston Scientific3.13%$3.91M$145.34B9.85%
79
Outperform
Madrigal Pharmaceuticals2.96%$3.70M$13.35B70.32%
56
Neutral

PTH Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
46.08
Positive
100DMA
42.45
Positive
200DMA
40.66
Positive
Market Momentum
MACD
1.53
Negative
RSI
75.37
Negative
STOCH
82.06
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PTH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 48.89, equal to the 50-day MA of 46.08, and equal to the 200-day MA of 40.66, indicating a bullish trend. The MACD of 1.53 indicates Negative momentum. The RSI at 75.37 is Negative, neither overbought nor oversold. The STOCH value of 82.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTH.

PTH Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$117.54M0.60%
60
Neutral
$896.18M0.62%
69
Neutral
$731.10M0.38%
69
Neutral
$725.16M0.40%
71
Outperform
$293.81M0.51%
65
Neutral
$138.32M0.29%
66
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PTH
Invesco DWA Healthcare Momentum ETF
52.99
7.79
17.23%
FXH
First Trust Health Care AlphaDEX Fund
IHF
iShares U.S. Healthcare Providers ETF
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
PINK
Simplify Health Care ETF
PSCH
Invesco S&P SmallCap Health Care ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement